The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1286
Desvenlafaxine for Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of desvenlafaxine (Pristiq – Wyeth), the main active metabolite of venlafaxine (Effexor, and others – Wyeth), for treatment of major depressive disorder. Venlafaxine, a norepinephrine and serotonin reuptake inhibitor (SNRI), is available generically as an immediate-release tablet. Venlafaxine extended-release capsules (Effexor XR) are scheduled to go off-patent in 2010.

VENLAFAXINE — Originally positioned as a secondline drug,1 venlafaxine has recently been marketed directly to the public as a first-line treatment for depression. Its adverse effects are similar to those of the selective serotonin reuptake inhibitors (SSRIs), but discontinuation symptoms may be more severe, it can cause a slight increase in diastolic blood pressure, and it appears to be more dangerous in overdose.2

PHARMACOLOGY ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Desvenlafaxine for Depression
Article code: 1286a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian